Skip to main content
Back
Watch Compare

BioRestorative Therapies, Inc.

Data quality: 100%
BRTX
Nasdaq Services Health Services
$0.25
▼ $0.01 (-4.17%)
Mkt Cap: 6.27 M
Price
$0.25
Mkt Cap
6.27 M
Day Range
$0.25 — $0.26
52-Week Range
$0.19 — $2.05
Volume
1,000,070
Open $0.26
50D / 200D Avg
$0.47
47.79% below
50D / 200D Avg
$1.19
79.27% below

Quick Summary

Key Takeaways

Revenue grew 67.22% annually over 5 years — strong growth
Negative free cash flow of -10.91 M
Revenue growth is decelerating — 1Y growth trails 5Y average by 77.52%
Capital intensive — 32.27% of revenue goes to capex

Growth

Revenue Growth (5Y)
67.22%
Above sector avg (4.21%)
Revenue (1Y)-10.30%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Quality

Return on Equity
-403.90%
Below sector avg (-15.74%)
ROIC-350.56%
Net Margin-3959.40%
Op. Margin-4350.05%

Safety

Debt / Equity
N/A
Current Ratio1.37
Interest Coverage-58.78

Valuation

PE (TTM)
-0.44
Above sector avg (-1.17)
P/B Ratio2.84
EV/EBITDAN/A
Dividend YieldN/A

Price History

Financial Trends

Peer Comparison

vs Services sector median (502 peers)
Metric Stock Sector Median
P/E -0.4 -1.2
P/B 2.8 1.4
ROE % -403.9 -15.7
Net Margin % -3959.4 -18.3
Rev Growth 5Y % 67.2 4.2
D/E — 0.4

All Fundamental Metrics
Growth
Revenue Growth (1Y) -10.30% Revenue Growth (3Y) 57.07%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 67.22% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 359,700.0 Net Income (TTM) -14.24 M
ROE -403.90% ROA -201.17%
Gross Margin 93.37% Operating Margin -4350.05%
Net Margin -3959.40% Free Cash Flow (TTM) -10.91 M
ROIC -350.56% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 1.37
Interest Coverage -58.78 Asset Turnover 0.05
Working Capital 1.27 M Tangible Book Value 1.65 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -0.44 Forward P/E N/A
P/B Ratio 2.84 P/S Ratio 17.43
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -173.92%
Market Cap 6.27 M Enterprise Value 5.67 M
Per Share
EPS (Diluted TTM) -1.58 Revenue / Share 0.01
FCF / Share -0.43 OCF / Share -0.42
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 32.27% FCF Conversion 76.57%
SBC-Adj. FCF -14.07 M Growth Momentum -77.52

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 359,700.0 401,000.0 145,800.0 119,800.0 46,000.0
Net Income -14.24 M -8.98 M -14.42 M -18.49 M -44.30 M
EPS (Diluted) -1.58 -1.16 -3.42 — —
Gross Profit 335,856.0 372,928.0 — — —
Operating Income -15.65 M -11.56 M -15.22 M -18.97 M -26.31 M
EBITDA — — — — —
R&D Expenses 10.09 M 5.35 M 4.03 M 3.51 M 729,058.0
SG&A Expenses — — — — —
D&A 209,985.0 189,056.0 165,735.0 120,545.0 89,108.0
Interest Expense 266,207.0 616,077.0 552,293.0 11,650.0 —
Income Tax — — — — —

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 4.08 M 12.28 M 12.61 M 16.43 M 22.45 M
Total Liabilities — 3.75 M 1.06 M 602,619.0 856,497.0
Shareholders' Equity 356,744.0 8.53 M 11.55 M 15.83 M 21.60 M
Total Debt — — — — 250,000.0
Cash & Equivalents 1.51 M 547,890.0 884,377.0 1.68 M —
Current Assets 3.14 M 11.14 M 11.39 M 15.13 M 21.47 M
Current Liabilities 3.72 M 3.75 M 1.06 M 440,302.0 363,822.0